tiprankstipranks
Pliant Therapeutics (PLRX)
NASDAQ:PLRX

Pliant Therapeutics Stock Analysis & Ratings

Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

PLRX FAQ

What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $3.96 and its highest was $24.17 in the past 12 months.
    What is Pliant Therapeutics’s market cap?
    Currently, no data Available
    What is Pliant Therapeutics’s price target?
    The average price target for Pliant Therapeutics is $43.56. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $53.00 ,the lowest forecast is $33.00. The average price target represents 112.18% Increase from the current price of $20.53.
      What do analysts say about Pliant Therapeutics?
      Pliant Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
        When is Pliant Therapeutics’s upcoming earnings report date?
        Pliant Therapeutics’s upcoming earnings report date is Aug 16, 2022 which is in 4 days.
          How were Pliant Therapeutics’s earnings last quarter?
          Pliant Therapeutics released its earnings results on May 09, 2022. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.749 by -$0.031.
            Is Pliant Therapeutics overvalued?
            According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Pliant Therapeutics pay dividends?
              Pliant Therapeutics does not currently pay dividends.
              What is Pliant Therapeutics’s EPS estimate?
              Pliant Therapeutics’s EPS estimate is -$0.81.
                How many shares outstanding does Pliant Therapeutics have?
                Pliant Therapeutics has 46,980,278 shares outstanding.
                  What happened to Pliant Therapeutics’s price movement after its last earnings report?
                  Pliant Therapeutics reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.749. Following the earnings report the stock price went up 4.709%.
                    Which hedge fund is a major shareholder of Pliant Therapeutics?
                    Among the largest hedge funds holding Pliant Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Pliant Therapeutics’s shares valued at N/A.

                      ---

                      Pliant Therapeutics Stock Analysis

                      Smart Score
                      10
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $43.56
                      ▲(112.18% Upside)
                      Strong Buy
                      The Pliant Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Pliant Therapeutics

                      Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Johnson & Johnson
                      Eli Lilly & Co
                      Pfizer
                      Merck & Company
                      Bristol Myers

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis